Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.

Alifrangis, C; Thornton, A; Fotopoulou, C; Krell, J; Gabra, H

Alifrangis, C; Thornton, A; Fotopoulou, C; Krell, J; Gabra, H.

Afiliação

Alifrangis C; Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom.
Thornton A; Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom.
Fotopoulou C; Dept. of Gynaecology, Imperial College London, United Kingdom.
Krell J; Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom; Division of Cancer, Imperial College London, United Kingdom.
Gabra H; Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom; Division of Cancer, Imperial College London, United Kingdom.

Gynecol Oncol Rep ; 18: 42-44, 2016 Nov.

Article em En | MEDLINE | ID: mdl-27872893

Palavras-chave

Clear cell; Drug resistance; Targeted therapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Gynecol Oncol Rep Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google